Angela Zhou is an Information Scientist at CAS. She earned her Ph.D. in Molecular Pharmacology and toxicology from University of Southern California. She was further trained as a cell biologist at Johns Hopkins School of Medicine and worked in the area of cancer biology at Harvard Medical School. She was a faculty member at Missouri State University and Denison University prior to joining CAS.
Latest Content from Angela Zhou
November 18, 2021
Are psychedelics next to treat depression and PTSD?
Recent clinical trials show that psychedelics like LSD, MDMA, and Psilocybin - when properly controlled for dosing and administration - are having positive outcomes in treating mental health disorders. Read about the latest research.
With increased interest in drug R&D seeking to unlock previously “undruggable” targets, there are crucial questions which must be answered to ensure that these approaches reach their potential. Join us at this virtual event and learn more.
Since the outbreak of COVID-19, caused by SARS-CoV-2 virus, scientists have been racing to understand it. Extensive research has been devoted to identifying viable genes and proteins as targets for therapeutic agents. One particular protein that has drawn considerable attention is the human cell’s viral receptor, angiotensin-converting enzyme 2 (ACE2).